Surgical Science Sweden (SUS.ST) Stock Analysis & AI Equity Report
Surgical Science Sweden (SUS.ST) overview
Surgical Science Sweden (SUS.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Surgical Science Sweden reported revenue of SEK 992m and operating profit of SEK 109m; the year-end share price was 32.50 SEK and market capitalisation was SEK 1,658m. Surgical Science Sweden is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Surgical Science Sweden's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Surgical Science Sweden
Surgical Science Sweden AB develops and sells medical simulation training products and software for healthcare education and MedTech companies. Its portfolio includes virtual reality simulators, customizable curricula, and performance-reporting tools used for laparoscopic, robotic, endoscopy, and other procedures. The company serves hospitals, training centers, and device manufacturers through direct sales and partnerships globally.
Generate the Surgical Science Sweden report
Surgical Science Sweden is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Surgical Science Sweden and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.